Created with Highcharts 7.2.2
Loading...
Calendar Year
 Fund
 Category
 Benchmark
Collapse All Sections

MF Analysis and Calculating Mutual Fund Returns

Collapse

Mutual fund analysis and return ratios


portfolio holding

Collapse

Portfolio holding for


Equity Holding


Healthcare (98.5%) Finance (1.4%)
Invested In
Sector
Market Value Latest Price
Value as of
31 Mar, 2025
% of Total Holding
Quantity
Month Change
in Shares
Month Change
in Shares %
History
Healthcare
335.22
325.33
10.78%
1,875.5 K
-
-
Healthcare
284.6
286.55
9.49%
2,489.5 K
-
-
Healthcare
273.21
258.22
8.55%
1,790.5 K
-
-
Healthcare
227.61
240.9
7.98%
1,604 K
-
-
Globus Medical Inc Class A
Healthcare
-
168.39
5.58%
268.8 K
-
-
Healthcare
133.3
146.61
4.86%
920.7 K
-
-
Healthcare
138.76
136.04
4.51%
2,217.9 K
-
-
Healthcare
124.63
132.36
4.38%
1,423.6 K
-
-
Healthcare
135.42
128.86
4.27%
194.8 K
-
-
Healthcare
109.83
121.52
4.03%
1,597.1 K
-
-
Page
of 4
Loading Mutual Funds...
*All financials are in Rs Crores
* Holding as on 31 Mar, 2025

MF Fund Details and Expense Ratio

Collapse

Mutual Fund Details and Expense Ratio

Basic Information

Fund Company
DSP Mutual Fund
Website
www.dspim.com
Inception
Nov 30, 2018
ISIN
INF740KA1LD8

Fund Manager

Chirag Dagli
Tenure: 4 Yrs 4 Mos
Start Date: 2020-12-01

AMC Details

Name
DSP Asset Managers Private Limited
Launch Date
Dec 4 2018
Fax
NA
Phone
+91 18002084499
Website
www.dspim.com
Address
, ,

Registrar Details

Name
Computer Age Management Services Ltd
Launch Date
Dec 4 2018
E-mail
enq_L@camsonline.com
Fax
91-44-28283610
Phone
NA
Address
New No.10, Old No.178, Kodambakkam High Road, Opp. Hotel Palmgrove, Nungambakkam, Chennai, Tamil Nadu 600 034

Minimum Investment and MIP

Minimum SIP (AIP)
100.0 Rs
Min. Initial Purchase
100 Rs
Min. Additional Purchase
100 Rs
Net Expense Ratio
1.93 %

Other Details

AUM
3018.76 Cr
Benchmark
BSE Healthcare PR
Exit Loads
0 - 1 Months : 0.5 %
Scheme Objective
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there can be no assurance that the investment objective of the scheme will be realized.